HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity

The oral thrombin inhibitor ximelagatran was withdrawn in the late clinical trial phase because it adversely affected the liver. In approximately 8% of treated patients, drug-induced liver injury (DILI) was expressed as transient alanine transaminase (ALT) elevations. No evidence of DILI had been re...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundgren, Hanna, Martinsson, Klara, Cederbrant, Karin, Jirholt, Johan, Mucs, Daniel, Madeyski-Bengtson, Katja, Havarinasab, Said, Hultman, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608249/
https://www.ncbi.nlm.nih.gov/pubmed/28934241
http://dx.doi.org/10.1371/journal.pone.0184744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608249/
https://www.ncbi.nlm.nih.gov/pubmed/28934241
http://dx.doi.org/10.1371/journal.pone.0184744

Ejemplares similares